Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Insights into Chronic Liver Disease and Hepatocellular Carcinoma
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Insights into Chronic Liver Disease and Hepatocellular Carcinoma

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 January 2025 | Viewed by 3911

Special Issue Editor

Dr. Marios Papadakis

E-Mail Website
Guest Editor
Department of Surgery II, University Hospital Witten-Herdecke, University of Witten-Herdecke, Heusnerstrasse 40, 42283 Wuppertal, Germany
Interests: skin cancer; oncology; dermatologic surgery; wound healing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Chronic liver diseases, spanning a spectrum from metabolic disorders to viral hepatitis, have become a significant global health challenge, impacting millions of individuals worldwide. Hepatocellular carcinoma (HCC), a major consequence of chronic liver diseases, stands as a leading cause of cancer-related morbidity and mortality. The rising prevalence of these conditions underscores the critical need for publishing advanced insights to inform diagnostic, prognostic, and therapeutic strategies.

Key Themes and Research Topics:

  • Diagnostic Biomarkers for Early Detection: Uncover novel diagnostic biomarkers crucial for the early identification of chronic liver diseases, specifically aiming to pinpoint individuals at heightened risk for HCC.
  • Genetic and Epigenetic Profiling: Investigate genetic and epigenetic factors influencing susceptibility, progression, and response to treatment in chronic liver diseases and hepatocellular carcinoma.
  • Metabolic Reprogramming in Hepatic Diseases: Explore the metabolic alterations in liver cells contributing to the development and progression of hepatocellular carcinoma.
  • Microenvironmental Influences in Liver Cancer: Examine the intricate interplay between the tumor microenvironment and the initiation and advancement of hepatocellular carcinoma.
  • Immunomodulation in Chronic Liver Conditions: Explore the dynamics of mucosal immunology within the liver and its impact on chronic liver diseases, including autoimmune liver disease and viral hepatitis.

This special issue, supervised by Dr. Marios Papadakis and assisted by our Topical Advisory Panel Member Dr. Stavros P. Papadakos (National and Kapodistrian University of Athens, Greece), aims to significantly contribute to our understanding of liver-related health challenges. By fostering research on these key themes, this Special Issue aspires to enhance global efforts in the diagnosis, treatment, and prevention of chronic liver diseases and HCC.

Dr. Marios Papadakis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic liver disease
  • hepatocellular carcinoma
  • tumor microenvironment
  • viral hepatitis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 3940 KiB  
Article
Biomarker Discovery in Liver Disease Using Untargeted Metabolomics in Plasma and Saliva
by Noah J. Daniels, Courtney E. Hershberger, Matthew Kerosky, Chase J. Wehrle, Roma Raj, Nihal Aykun, Daniela S. Allende, Federico N. Aucejo and Daniel M. Rotroff
Int. J. Mol. Sci. 2024, 25(18), 10144; https://doi.org/10.3390/ijms251810144 - 21 Sep 2024
Viewed by 1074
Abstract
Chronic liver diseases, including non-alcoholic fatty liver disease (NAFLD), cirrhosis, and hepatocellular carcinoma (HCC), continue to be a global health burden with a rise in incidence and mortality, necessitating a need for the discovery of novel biomarkers for HCC detection. This study aimed [...] Read more.
Chronic liver diseases, including non-alcoholic fatty liver disease (NAFLD), cirrhosis, and hepatocellular carcinoma (HCC), continue to be a global health burden with a rise in incidence and mortality, necessitating a need for the discovery of novel biomarkers for HCC detection. This study aimed to identify novel non-invasive biomarkers for these different liver disease states. We performed untargeted metabolomics in plasma (Healthy = 9, NAFLD = 14, Cirrhosis = 10, HCC = 34) and saliva samples (Healthy = 9, NAFLD = 14, Cirrhosis = 10, HCC = 22) to test for significant metabolite associations with each disease state. Additionally, we identified enriched biochemical pathways and analyzed correlations of metabolites between, and within, the two biofluids. We identified two salivary metabolites and 28 plasma metabolites significantly associated with at least one liver disease state. No metabolites were significantly correlated between biofluids, but we did identify numerous metabolites correlated within saliva and plasma, respectively. Pathway analysis revealed significant pathways enriched within plasma metabolites for several disease states. Our work provides a detailed analysis of the altered metabolome at various stages of liver disease while providing some context to altered pathways and relationships between metabolites. Full article
(This article belongs to the Special Issue Insights into Chronic Liver Disease and Hepatocellular Carcinoma)
►▼ Show Figures

Figure 1

19 pages, 11910 KiB  
Article
High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance Spectroscopy of Paired Clinical Liver Tissue Samples from Hepatocellular Cancer and Surrounding Region
by Wendy M. Fernandes, Nicola Harris, Ane Zamalloa, Lissette Adofina, Parthi Srinivasan, Krishna Menon, Nigel Heaton, Rosa Miquel, Yoh Zen, Geoff Kelly, James A. Jarvis, Alain Oregioni, Shilpa Chokshi, Antonio Riva and I. Jane Cox
Int. J. Mol. Sci. 2024, 25(16), 8924; https://doi.org/10.3390/ijms25168924 - 16 Aug 2024
Viewed by 1028
Abstract
The global burden of liver cancer is increasing. Timely diagnosis is important for optimising the limited available treatment options. Understanding the metabolic consequences of hepatocellular carcinoma (HCC) may lead to more effective treatment options. We aimed to document metabolite differences between HCC and [...] Read more.
The global burden of liver cancer is increasing. Timely diagnosis is important for optimising the limited available treatment options. Understanding the metabolic consequences of hepatocellular carcinoma (HCC) may lead to more effective treatment options. We aimed to document metabolite differences between HCC and matched surrounding tissues of varying aetiology, obtained at the time of liver resection, and to interpret metabolite changes with clinical findings. High-resolution magic angle spinning nuclear magnetic resonance (HRMAS-NMR) spectroscopy analyses of N = 10 paired HCC and surrounding non-tumour liver tissue samples were undertaken. There were marked HRMAS-NMR differences in lipid levels in HCC tissue compared to matched surrounding tissue and more subtle changes in low-molecular-weight metabolites, particularly when adjusting for patient-specific variability. Differences in lipid-CH3, lipid-CH2, formate, and acetate levels were of particular interest. The obvious differences in lipid content highlight the intricate interplay between metabolic adaptations and cancer cell survival in the complex microenvironment of liver cancer. Differences in formate and acetate might relate to bacterial metabolites. Therefore, documentation of metabolites in HCC tissue according to histology findings in patients is of interest for personalised medicine approaches and for tailoring targeted treatment strategies. Full article
(This article belongs to the Special Issue Insights into Chronic Liver Disease and Hepatocellular Carcinoma)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

26 pages, 1294 KiB  
Review
Diagnostic Performances of PET/CT Using Fibroblast Activation Protein Inhibitors in Patients with Primary and Metastatic Liver Tumors: A Comprehensive Literature Review
by Federica Manuppella, Giusi Pisano, Silvia Taralli, Carmelo Caldarella and Maria Lucia Calcagni
Int. J. Mol. Sci. 2024, 25(13), 7197; https://doi.org/10.3390/ijms25137197 - 29 Jun 2024
Viewed by 1260
Abstract
PET/CT using radiolabeled fibroblast activation protein inhibitors (FAPIs) is a promising diagnostic tool in oncology, especially when non-increased and/or physiologically high [18F]FDG uptake (as in liver parenchyma) is observed. We aimed to review the role of PET/CT using radiolabeled FAPIs in [...] Read more.
PET/CT using radiolabeled fibroblast activation protein inhibitors (FAPIs) is a promising diagnostic tool in oncology, especially when non-increased and/or physiologically high [18F]FDG uptake (as in liver parenchyma) is observed. We aimed to review the role of PET/CT using radiolabeled FAPIs in primary and/or metastatic liver lesions, and to compare their performances with more “conventional” radiopharmaceuticals. A search algorithm based on the terms “FAPI” AND (“hepatic” OR “liver”) was applied, with the last update on 1st January 2024. Out of 177 articles retrieved, 76 studies reporting on the diagnostic application of radiolabeled FAPI PET/CT in at least one patient harboring primary or metastatic liver lesion(s) were fully analyzed. Although there was some heterogeneity in clinical conditions and/or study methodology, PET/CT with radiolabeled FAPIs showed an excellent performance in common primary liver malignancies (hepatocarcinoma, intrahepatic cholangiocarcinoma) and liver metastases (mostly from the gastrointestinal tract and lungs). A higher tumor-to-background ratio for FAPIs than for [18F]FDG was found in primary and metastatic liver lesions, due to lower background activity. Despite limited clinical evidence, radiolabeled FAPIs may be used to assess the suitability and effectiveness of FAPI-derived therapeutic agents such as [177Lu]Lu-FAPI. However, future prospective research on a wider population is needed to confirm the excellent performance. Full article
(This article belongs to the Special Issue Insights into Chronic Liver Disease and Hepatocellular Carcinoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop